Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 8

1.

Hepatic differentiation of human iPSCs in different 3D models: A comparative study.

Meier F, Freyer N, Brzeszczynska J, Knöspel F, Armstrong L, Lako M, Greuel S, Damm G, Ludwig-Schwellinger E, Deschl U, Ross JA, Beilmann M, Zeilinger K.

Int J Mol Med. 2017 Dec;40(6):1759-1771. doi: 10.3892/ijmm.2017.3190. Epub 2017 Oct 16.

2.

Usefulness of A Model-Based Approach for Estimating In Vitro P-Glycoprotein Inhibition Potency in a Transcellular Transport Assay.

Kishimoto W, Ishiguro N, Ludwig-Schwellinger E, Ebner T, Maeda K, Sugiyama Y.

J Pharm Sci. 2016 Feb;105(2):891-896. doi: 10.1016/j.xphs.2015.11.006.

PMID:
26869433
3.

Sex-, Species-, and Tissue-Specific Metabolism of Empagliflozin in Male Mouse Kidney Forms an Unstable Hemiacetal Metabolite (M466/2) That Degrades to 4-Hydroxycrotonaldehyde, a Reactive and Cytotoxic Species.

Taub ME, Ludwig-Schwellinger E, Ishiguro N, Kishimoto W, Yu H, Wagner K, Tweedie D.

Chem Res Toxicol. 2015 Jan 20;28(1):103-15. doi: 10.1021/tx500380t. Epub 2015 Jan 5.

PMID:
25489797
4.

In vitro predictability of drug-drug interaction likelihood of P-glycoprotein-mediated efflux of dabigatran etexilate based on [I]2/IC50 threshold.

Kishimoto W, Ishiguro N, Ludwig-Schwellinger E, Ebner T, Schaefer O.

Drug Metab Dispos. 2014 Feb;42(2):257-63. doi: 10.1124/dmd.113.053769. Epub 2013 Nov 8.

PMID:
24212378
5.

Impact of endogenous esterase activity on in vitro p-glycoprotein profiling of dabigatran etexilate in Caco-2 monolayers.

Ishiguro N, Kishimoto W, Volz A, Ludwig-Schwellinger E, Ebner T, Schaefer O.

Drug Metab Dispos. 2014 Feb;42(2):250-6. doi: 10.1124/dmd.113.053561. Epub 2013 Nov 8.

PMID:
24212377
6.

Simultaneous absolute protein quantification of transporters, cytochromes P450, and UDP-glucuronosyltransferases as a novel approach for the characterization of individual human liver: comparison with mRNA levels and activities.

Ohtsuki S, Schaefer O, Kawakami H, Inoue T, Liehner S, Saito A, Ishiguro N, Kishimoto W, Ludwig-Schwellinger E, Ebner T, Terasaki T.

Drug Metab Dispos. 2012 Jan;40(1):83-92. doi: 10.1124/dmd.111.042259. Epub 2011 Oct 12.

PMID:
21994437
7.

The metabolism and disposition of the oral dipeptidyl peptidase-4 inhibitor, linagliptin, in humans.

Blech S, Ludwig-Schwellinger E, Gräfe-Mody EU, Withopf B, Wagner K.

Drug Metab Dispos. 2010 Apr;38(4):667-78. doi: 10.1124/dmd.109.031476. Epub 2010 Jan 19.

PMID:
20086031
8.

The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans.

Blech S, Ebner T, Ludwig-Schwellinger E, Stangier J, Roth W.

Drug Metab Dispos. 2008 Feb;36(2):386-99. Epub 2007 Nov 15.

PMID:
18006647

Supplemental Content

Loading ...
Support Center